The Cancer Letter

Inside information on cancer research and drug development

Drugs & Targets

FDA grants orphan drug status to Cellect’s ApoGraft for acute and chronic GvHD

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

Cellect Biotechnology Ltd. said the FDA has granted orphan drug designation for Cellect’s ApoGraft for the prevention of acute and chronic graft versus host disease in transplant patients.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Table of Contents

Login

Site license subscribers:
Log in with your IP | Register a sponsored account